UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

GSK PLC GSK shares inched up 0.03% to £14.97 Thursday, on what proved to be an all-around favorable trading session for the ...

GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger ...

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

Oct 8 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...

Under the agreement, whose terms are confidential, GSK will make an "aggregate payment of up to $2.2 billion" to resolve ...

GSK GSK-0.10%decrease; red down pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.